Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Immunotherapy is effective in recurrent endometrial cancer (EC), particularly in patients harboring a deficit in the DNA mismatch repair system (dMMR) or with microsatellite instability-high (MSI-H) tumors. Currently, for patients with advanced disease in progression to platinum-based chemotherapy, dostarlimab or pembrolizumab used as a monotherapy are considered the standard of care for the dMMR/MSI-H subgroup. Additionally, pembrolizumab plus lenvatinib have been approved for both pMMR and dMMR/MSI-H patients.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Michele Bartoletti, Marcella Montico, Domenica Lorusso, Roberta Mazzeo, Ana Oaknin, Lucia Musacchio, Giovanni Scambia, Fabio Puglisi, Sandro Pignata Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Endometrial Cancer | Gastroschisis Repair | Immunotherapy | Study